<DOC>
	<DOCNO>NCT02698059</DOCNO>
	<brief_summary>This post-marketing surveillance study investigate efficacy safety Negative Pressure Sleep Therapy System treatment obstructive sleep apnea .</brief_summary>
	<brief_title>A Post-marketing Surveillance Negative Pressure Sleep Therapy System Treat Obstructive Sleep Apnea</brief_title>
	<detailed_description>This multi-center , two-stage , single-arm , prospective , first-night order cross-over , evaluator-blind , post-marketing surveillance study evaluate efficacy , safety tolerance iNAP® Sleep Therapy System ( iNAP ) , tongue soft palate retain intraoral device , adult obstructive sleep apnea ( OSA ) .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>1 ) Female male adult age 18~65 year old . ( S1 ) 2 ) Nonobese patient body mass index ( BMI ) &lt; 29 kg/m2 . ( S1 ) 3 ) Patients able read sign inform consent form able comply study requirement . ( S1 ) 4 ) Patients able properly fitted* oral interface observe device feasibility test . ( S1 ) 5 ) Patients oxygen desaturation index ( ODI ) 10~40 ( S2 ) . 6 ) Patients oral negative vacuum time maintained* iNAP® ≥4 hours/night total sleep time ( TST ) ≥4 hours/night ( S3 ) . iNAP® pressure negative 30 mmHg consider evidence effective oral appliance application . 7 ) Patients apneahypopnea index ( AHI ) 10~40 TST ≥4 hours/night ( Baseline PSG Night ) . 8 ) Patients oral negative vacuum time maintained* iNAP® ≥4 hours/night TST ≥4 hours/night ( 1st Tx PSG Night ) . iNAP® pressure negative 30 mmHg consider evidence effective oral appliance application . 1 ) Patients allergic silicone . 2 ) Patients obstruct nasal passage evidence inability breathe nose mouth close . 3 ) Patients recently experience nearmiss prior automobile accident due sleepiness . 4 ) Patients hypoxemia ( SpO2 &lt; 80 % ) past six month cause disease OSA cardiac disease severe pulmonary/respiratory disorder chronic obstructive pulmonary disease ( COPD ) , interstitial lung disease , pneumothorax , pneumonia , etc . 5 ) Female patient lactate , pregnant intend become pregnant study period . 6 ) Patients primary insomnia concomitant diagnose suspected sleep disorder . 7 ) Patients muscle disease , central nervous disease chronic neurological disorder , include central sleep apnea* . Central sleep apnea define central apnea index ( CAI ) ≥ 5/hr central sleep apnea account ≥ 50 % total AHI . 8 ) Patients suitable use iNAP® opinion Investigator include , limited , alcohol substance abuse , loose teeth , miss teeth , grind teeth , complete deviated septum ( Type IV VII ) complete closed nostril advance periodontal disease tonsillar volume great grade 3 . 9 ) Patients inability sleep night include , limited , menopausal hot flash , work night rotate night shift , plan travel across four time zone study period within one week prior study participation , sleep schedule compatible study site practice . 10 ) Patients potential complication sleep apnea , opinion Investigator , may affect study interpretation health safety patient include , limited , narcolepsy , restless leg syndrome , nasopharyngeal carcinoma ( NPC ) , end stage renal failure , history severe cardiovascular disease ( include New York Heart Association ( NYHA ) class III IV cardiac failure , coronary artery disease angina myocardial infarction/stroke past six month , uncontrolled hypertension hypotension cardiac arrhythmia ) , unstable heart renal transplantation use medicine treatment ( ) may confound result study pose additional risk patient , oral anticoagulant agent make patient prone tongue hemorrhage . Stage II Patients fulfill enrollment criterion Stage I whose treat AHI 1st Tx PSG Night 40 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>